Sequenom Launches DNA-Methylation Service as Field Begins to Gather Steam | GenomeWeb

SALT LAKE CITY — DNA-methylation analysis appears to be gathering momentum as an approach parallel to — or even competing with — genotyping and gene-expression analysis in pharmacogenomics applications.

After recently hinting at a move toward, Sequenom has taken the plunge and announced a service offering in that market. When asked whether Sequenom intended to look into fetal gene expression in maternal blood, Harry Stylli told Pharmacogenomics Reporter that "if you look at methylation markers, they're involved in gene regulation."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.